Limits...
Antilymphocyte antibodies in systemic lupus erythematosus: association with disease activity and lymphopenia.

Li C, Mu R, Lu XY, He J, Jia RL, Li ZG - J Immunol Res (2014)

Bottom Line: In multivariate analyses, ALA was independently associated with lymphopenia, higher SLEDAI scores, and increased risk for LN.ALA titers significantly decreased as clinical disease was ameliorated following treatment.ALA occurred more frequently in patients with active SLE and was independently associated with lymphopenia, disease activity, and LN.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology and Immunology, Peking University People's Hospital, 11 South Xizhimen Street, Beijing 100044, China.

ABSTRACT

Purpose: We analyzed the prevalence, clinical correlation, and the functional significance of ALA in patients with systemic lupus erythematosus (SLE).

Methods: ALA IgG was detected by indirect immunofluorescence in the serum of 130 SLE patients, 75 patients with various rheumatic diseases, and 45 healthy controls (HC).

Results: The sensitivity and specificity of ALA IgG in SLE were 42.3% and 96.7%, respectively. ALA was observed in 55.6% (50/90) of patients with lymphopenia, which was significantly higher than in patients with normal lymphocytes (5/40, 12.5%; P<0.001). Patients with active SLE showed higher ALA positivity (60.9%) than those with inactive disease (24.2%; χ2=17.925; P<0.001). ALA correlated significantly with hypocomplementemia, anti-dsDNA antibodies, and higher SLEDAI scores. The incidences of ALA in SLE patients who were seronegative for anti-dsDNA, anti-Sm, or both antibodies were 32.9% (26/79), 41.0% (43/105), and 32.4% (22/68), respectively. The ALA-positive group also had higher incidences of neuropsychiatric SLE (NPSLE) and lupus nephritis (LN). In multivariate analyses, ALA was independently associated with lymphopenia, higher SLEDAI scores, and increased risk for LN. ALA titers significantly decreased as clinical disease was ameliorated following treatment.

Conclusions: ALA occurred more frequently in patients with active SLE and was independently associated with lymphopenia, disease activity, and LN.

Show MeSH

Related in: MedlinePlus

ALA titers before and after treatment in 20 patients with SLE. The ALA titers decreased significantly in accordance with clinical amelioration of disease following treatment (P = 0.014).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4016860&req=5

fig3: ALA titers before and after treatment in 20 patients with SLE. The ALA titers decreased significantly in accordance with clinical amelioration of disease following treatment (P = 0.014).

Mentions: ALA titers decreased significantly in accordance with disease amelioration following treatment in a subgroup of 20 patients with SLE (Figure 3). The SLEDAI scores in these 20 patients also decreased from 15.8 ± 6.2 to 3.6 ± 3.0 (P < 0.001).


Antilymphocyte antibodies in systemic lupus erythematosus: association with disease activity and lymphopenia.

Li C, Mu R, Lu XY, He J, Jia RL, Li ZG - J Immunol Res (2014)

ALA titers before and after treatment in 20 patients with SLE. The ALA titers decreased significantly in accordance with clinical amelioration of disease following treatment (P = 0.014).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4016860&req=5

fig3: ALA titers before and after treatment in 20 patients with SLE. The ALA titers decreased significantly in accordance with clinical amelioration of disease following treatment (P = 0.014).
Mentions: ALA titers decreased significantly in accordance with disease amelioration following treatment in a subgroup of 20 patients with SLE (Figure 3). The SLEDAI scores in these 20 patients also decreased from 15.8 ± 6.2 to 3.6 ± 3.0 (P < 0.001).

Bottom Line: In multivariate analyses, ALA was independently associated with lymphopenia, higher SLEDAI scores, and increased risk for LN.ALA titers significantly decreased as clinical disease was ameliorated following treatment.ALA occurred more frequently in patients with active SLE and was independently associated with lymphopenia, disease activity, and LN.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology and Immunology, Peking University People's Hospital, 11 South Xizhimen Street, Beijing 100044, China.

ABSTRACT

Purpose: We analyzed the prevalence, clinical correlation, and the functional significance of ALA in patients with systemic lupus erythematosus (SLE).

Methods: ALA IgG was detected by indirect immunofluorescence in the serum of 130 SLE patients, 75 patients with various rheumatic diseases, and 45 healthy controls (HC).

Results: The sensitivity and specificity of ALA IgG in SLE were 42.3% and 96.7%, respectively. ALA was observed in 55.6% (50/90) of patients with lymphopenia, which was significantly higher than in patients with normal lymphocytes (5/40, 12.5%; P<0.001). Patients with active SLE showed higher ALA positivity (60.9%) than those with inactive disease (24.2%; χ2=17.925; P<0.001). ALA correlated significantly with hypocomplementemia, anti-dsDNA antibodies, and higher SLEDAI scores. The incidences of ALA in SLE patients who were seronegative for anti-dsDNA, anti-Sm, or both antibodies were 32.9% (26/79), 41.0% (43/105), and 32.4% (22/68), respectively. The ALA-positive group also had higher incidences of neuropsychiatric SLE (NPSLE) and lupus nephritis (LN). In multivariate analyses, ALA was independently associated with lymphopenia, higher SLEDAI scores, and increased risk for LN. ALA titers significantly decreased as clinical disease was ameliorated following treatment.

Conclusions: ALA occurred more frequently in patients with active SLE and was independently associated with lymphopenia, disease activity, and LN.

Show MeSH
Related in: MedlinePlus